An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]

Conditions

Hereditary Angioedema (HAE)

Brief summary

1. Incidence and severity of treatment-emergent adverse events (TEAEs), 2. Plasma pharmacokinetics and concentrations of donidalorsen

Detailed description

1. The time-normalized number of investigator-confirmed HAE attacks (per month) over the period of 12 months., 3. The percentage of investigator-confirmed HAE attack-free participants over the period of 12 months., 4. The time-normalized number of moderate or severe investigatorconfirmed HAE attacks (per month) over the period of 12 months., 5. The number of participants with a clinical response defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in investigator-confirmed HAE attack rate over the period of 12 months., 6. The number of investigator-confirmed HAE attacks requiring rescue treatment (i.e., acute therapy) over the period of 12 months., 7. Change in PKK levels in plasma over the period of 12 months., 8. Changes in Pediatrics Quality of Life (PedsQL) scores for participants over the period of 12 months.

Related papers

No related papers found yet.

Interventions

DRUGISIS 721744

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
1. Incidence and severity of treatment-emergent adverse events (TEAEs), 2. Plasma pharmacokinetics and concentrations of donidalorsen	—

Secondary

Measure	Time frame
1. The time-normalized number of investigator-confirmed HAE attacks (per month) over the period of 12 months., 3. The percentage of investigator-confirmed HAE attack-free participants over the period of 12 months., 4. The time-normalized number of moderate or severe investigatorconfirmed HAE attacks (per month) over the period of 12 months., 5. The number of participants with a clinical response defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in investigator-confirmed HAE attack rate over the period of 12 months., 6. The number of investigator-confirmed HAE attacks requiring rescue treatment (i.e., acute therapy) over the period of 12 months., 7. Change in PKK levels in plasma over the period of 12 months., 8. Changes in Pediatrics Quality of Life (PedsQL) scores for participants over the period of 12 months.	—

Measure

Time frame

1. The time-normalized number of investigator-confirmed HAE attacks (per month) over the period of 12 months., 3. The percentage of investigator-confirmed HAE attack-free participants over the period of 12 months., 4. The time-normalized number of moderate or severe investigatorconfirmed HAE attacks (per month) over the period of 12 months., 5. The number of participants with a clinical response defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in investigator-confirmed HAE attack rate over the period of 12 months., 6. The number of investigator-confirmed HAE attacks requiring rescue treatment (i.e., acute therapy) over the period of 12 months., 7. Change in PKK levels in plasma over the period of 12 months., 8. Changes in Pediatrics Quality of Life (PedsQL) scores for participants over the period of 12 months.

—

Outcome results

None listed